|
|
Amgen Inc
AMGN's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Amgen Inc 's sales fell
in the first quarter of 2025 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 12.78 %
Amgen Inc realized net income compared to net loss a year ago in first quarter of 2025
• More on AMGN's Growth
|
|
Amgen Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.
Amgen Inc PEG ratio is at 3.65
|
| Company |
| |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.37.
• More on AMGN's Valuation
|
|
|
|
|
Amgen Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.
Amgen Inc PEG ratio is at 3.65
|
| Company |
| |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.37.
| | | |
